INOVIQ Ltd is an Australia-based biotechnology company developing diagnostics and therapeutics for cancer. The Company's commercialized products include EXO-NET exosome isolation technology for biomarker discovery and diagnostics development, and the hTERT test as an adjunct test for bladder cancer. The Company is also advancing clinical-stage diagnostics for the detection and monitoring of ovarian and breast cancers, and early-stage exosome therapeutics for solid tumors.

Employees

Sector

Pharmaceuticals

More about the company

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.1350AUD

Average target price

0.7000AUD

Spread / Average Target

+418.52%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - BAR1 LIFE

Revisions to estimates

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - BAR1 LIFE

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Australian S.E.			5-day change	1st Jan Change
- ^AUD	-.--%		-.--%	-

23/10	Inoviq CEO to Step Down	MT
27/08	INOVIQ Ltd Reports Earnings Results for the Full Year Ended June 30, 2026	CI

Market Cap	1.9Cr 1.34Cr 1.2Cr 1.1Cr 99.8L 1.87Cr 126.95Cr 13Cr 5.27Cr 67Cr 5.02Cr 4.91Cr 210.6Cr	P/E 2027 *	-3.38x	P/E 2028 *	13.5x
Enterprise Value	1.9Cr 1.34Cr 1.2Cr 1.1Cr 99.8L 1.87Cr 126.95Cr 13Cr 5.27Cr 67Cr 5.02Cr 4.91Cr 210.6Cr	EV / Sales 2027 *	13.6x	EV / Sales 2028 *	1.73x
Free-Float	66.05%	Yield 2027 *	-	Yield 2028 *	-

23/10	Inoviq CEO to Step Down	MT
27/08	INOVIQ Ltd Reports Earnings Results for the Full Year Ended June 30, 2026	CI
26/08	INOVIQ Ltd Auditor Raises 'Going Concern' Doubt	CI
25/06	Inoviq Says CAR-Exosome Platform Showed In Vitro Tumor-Killing Activity in Ovarian Cancer; Shares Down 4%	MT
18/02	INOVIQ Ltd Reports Earnings Results for the Half Year Ended December 31, 2025	CI
23/12	INOVIQ Appoints Chief Scientific Officer	MT
23/12	INOVIQ Limited Announces Management Changes, Effective January 12, 2026	CI
18/12	Inoviq says Peter Gunzburg elected to role of chairman	RE
27/11	Inoviq Ltd Elects Peter Gunzburg as Non-Executive Director	CI
27/11	Inoviq says chairman David Williams to step down at year-end	RE
17/25/17	INOVIQ Ltd Announces Appointment of Peter Gunzburg as A Non-Executive Director, Effective 20 October 2025	CI
13/25/13	Inoviq completes A$9.5 million placement	RE
09/25/09	Inoviq Ltd seeks trading halt	RE

07/23/07	INOVIQ AND PROMEGA ANNOUNCE GLOBAL JOINT MARKETING AGREEMENT FOR EXO-NET EXOSOME ISOLATION AND NUCLEIC ACID PURIFICATION SOLUTIONS	AQ
27/22/27	INOVIQ : IIQ Appendix 4C & Quarterly Activities Report - June 2022	PU
29/22/29	INOVIQ : IIQ Appendix 4C & Quarterly Activities Report - March 2022	PU
06/22/06	INOVIQ : Updated Investor Presentation	PU
07/21/07	BARD1 Life Sciences : Application for quotation of securities - BD1	PU

BAR1 LIFE Share Price Australian S.E.

Stocks

BD1

Pharmaceuticals

Valuation: BAR1 LIFE

Latest news: BAR1 LIFE

Press Releases: BAR1 LIFE

Managers and Directors: BAR1 LIFE

Other Pharmaceuticals

Financials

Company Profile

Analysts' Consensus

Annual profits - Rate of surprise

Manager	Title	Age	Since
Mark Edwards DFI	Director of Finance/CFO	-	02/11/2022
Rebecca Lim CTO	Chief Tech/Sci/R&D Officer	-	12/01/2026
Emma Ball PRN	Corporate Officer/Principal	-	22/04/2025

Director	Title	Age	Since
Philip Powell BRD	Director/Board Member	67	18/06/2019
Robert Johnston BRD	Director/Board Member	-	18/06/2019
Geoff Cumming CHM	Chairman	-	28/07/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BAR1 LIFE	-.--%	-.--%	-	-	1.34Cr
ELI LILLY AND COMPANY	+3.19%	+11.31%	+64.28%	+155.91%	1,26300Cr
JOHNSON & JOHNSON	-0.73%	+3.56%	+44.65%	+84.17%	66TCr
ABBVIE INC.	+1.41%	+3.24%	+35.25%	+108.88%	52TCr
ROCHE HOLDING AG	+0.42%	+3.20%	+55.81%	+72.50%	39TCr
MERCK & CO., INC.	+2.18%	+2.93%	+73.90%	+45.59%	37TCr
NOVARTIS AG	+1.12%	+4.52%	+34.76%	+58.24%	31TCr
ASTRAZENECA PLC	+6.96%	+8.86%	+11.95%	+36.20%	29TCr
AMGEN INC.	+1.15%	+6.09%	+56.15%	+82.25%	25TCr
GILEAD SCIENCES, INC.	+3.06%	+9.38%	+42.48%	+117.32%	21TCr
Average	+1.88%	+5.90%	+46.58%	+84.56%	47.35TCr
Weighted average by Cap.	+2.01%	+6.60%	+50.51%	+100.44%

	2027 *	2028 *
Net sales	14L 10L 9L 8L 7L 13.74L 9.35Cr 96.76L 38.84L 4.92Cr 36.96L 36.18L 16Cr	1.1Cr 77.39L 69.31L 63.75L 57.77L 1.08Cr 73Cr 7.6Cr 3.05Cr 39Cr 2.9Cr 2.84Cr 121.9Cr
Net income	-	-
Net Debt	-	-